About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

IL-6: A Marker for AML Chemo Sensitivity | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT06486350

IL-6: A Marker for AML Chemo Sensitivity

Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate fo...

Lead sponsor: Fujian Medical University Union Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Huifang Huang

CONTACT

13365910318 huanghuif@fjmu.edu.cn

Sponsors

Lead Sponsor

Fujian Medical University Union Hospital

In this prospective study, we will collect bone marrow supernatant samples from patients diagnosed with Acute Myeloid Leukemia (AML) to evaluate the levels of Interleukin-6 (IL-6). Our aim is to explore whether elevated IL-6 levels can serve as a predictive biomarker for poor treatment outcomes following standard chemotherapy regimens. The findings may help in stratifying patient risk and personalizing therapeutic approaches in AML treatment.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)";
•2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;
•3. Patients participate in the study accompanied by family members and sign informed consent documents.

Exclusion Criteria

•1. Patients with concurrent malignancies requiring treatment;
•2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV/AIDS;
•3. Major surgery performed within the last 21 days;
•4. Performance Status (PS) score \>3;
•5. Severe liver or kidney dysfunction or serious infection;
•6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.

Related studies

RECRUITINGPhase 1/2

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

NCT06704152 · AML, Adult Recurrent, ALL, Recurrent, Adult, and more

RECRUITINGPhase 2

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

NCT06022003 · AML, Adult, Refractory AML, and more

RECRUITINGPhase 1/2

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

NCT06420063 · AML, Acute Myeloid Leukemia, and more

RECRUITINGPhase 2

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

NCT06014489 · AML, Adult

RECRUITINGPhase 1

Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

NCT06027853 · AML, Adult

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 3, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment72

Start dateOct 2023

Last updatedJul 3, 2024

Condition

Locations shown

Fujian Medical University Union Hospital

Fuzhou, Fujian

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 3, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions